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ROLE OF MKL1 IN MEGAKARYOCYTOPOIESIS AND IN t(1;22)-ASSOCIATED ACUTE 
MEGAKARYOBLASTIC LEUKEMIA. James A. Troy (Sponsored by Diane S. Krause). 
Department of Laboratory Medicine, Yale University, School of Medicine, New Haven, CT. 
 
The t(1;22)(p13;q13) translocation creates a fusion of the genes RBM15 and MKL1 and is 
exclusively associated with the infantile form of Acute Megakaryoblastic Leukemia, or AML 
variant M7. Although MKL1 is a known coactivator of the Serum Response Factor (SRF) 
pathway, it is not known whether MKL1 plays an important role in megakaryocytic commitment 
or differentiation. This project investigated the role of MKL1 in normal megakaryocytopoiesis by 
using a human CD34+ hematopoietic stem cell (HSC) model. Human CD34+ HSCs were 
transduced with lentiviral vectors expressing either MKL1 or dominant negative MKL1 (DN-
MKL1) and were cultured in conditions promoting megakaryocytopoiesis. After nine days, cells 
transduced with MKL1-expressing virus had increased expression of the megakaryocyte-
associated markers CD41a (52±10% vs. 28±15%), CD61 (5 ±15% vs. 26±13%) and CD42b 
(46±17% vs. 14±5%) when compared to cells transduce with the vector alone (all p < 0.05). 
Transduction with the DN-MKL1 lentivirus was unexpect dly also associated with an increase in 
these same markers, though this experiment was only performed once and will require further 
investigation. In separate megakaryocyte progenitor assays, MKL1 was associated with an 
increased frequency of megakaryocyte colony forming u its (CFU-Mk) (263±111 vs. 164±61 
CFU-Mk per 10,000 cells), though these data did not reach statistical significance. These findings 
suggest that MKL1 may be an important regulator of megakaryocytopoiesis, and that abnormal 
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  1   
Introduction 
 
Acute Megakaryoblastic Leukemia 
 Acute megakaryoblastic leukemia (AMKL), also referred to as acute myeloid 
leukemia (AML) variant M7, is characterized by infiltration of the bone marrow by 20% 
or more megakaryoblasts and circulation of these blasts in the peripheral blood. [1] 
Patients with AMKL typically exhibit the signs and symptoms of pancytopenia (anemia, 
thrombocytopenia and neutropenia), including fatigue, weakness, petechiae, purpura and 
impaired immune function. AMKL is also generally associated with extensive 
myelofibrosis and reticulin fiber deposition in the marrow, which can further exacerbate 
the symptoms related to bone marrow failure. AMKL most commonly occurs in children 
with one of two cytogenetic abnormalities: trisomy 21 (Down syndrome) or 
t(1;22)(p13;q13), a translocation involving chromosomes 1 and 22. In adults, AMKL 
occurs at a lower frequency and is associated with a wide range of cytogenetic changes 
and complex karyotypes that are different than those most commonly seen in children. 
 
Down syndrome associated AMKL (DS-AMKL) 
 DS-AMKL is the most common form of AMKL. Approximately 10% of children 
with Down syndrome are born with a condition called Transient Myeloproliferative 
Disorder (TMD), in which immature megakaryoblasts are found in the liver, bone 
marrow and blood. [2] Although most cases of TMD resolve spontaneously, as many as 
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30% of these cases progress to AMKL and require medical intervention. Overall, the 
incidence of AMKL is approximately 500 times greater in children with Down syndrome 
than in the general pediatric population, and AMKL accounts for approximately 62-86% 
of all AML in these children. [3, 4]  
Both AMKL and TMD in patients with Down syndrome are associated with 
various mutations of the X-linked GATA-1 gene that lead to the production of a truncated 
GATA-1 protein referred to as GATA-1 short (GATA-1s). [5] Investigations into the 
function of GATA-1 using GATA-1-/- embryonic stem (ES) cells and GATA-1-/- mice 
have demonstrated that the loss of GATA-1 is associated with hyperproliferation and 
failed differentiation of erythro-megakaryocytic precursors. [6, 7] However, DS-AMKL 
and non-DS-AMKL have been shown to have very different gene expression profiles, [8, 
9] suggesting that these forms of AMKL may lead to megakaryoblastic leukemogenesis 
by drastically different mechanisms. This is furthe supported by the vastly improved 
response to therapy in DS-AMKL versus non-DS-AMKL. Down syndrome patients with 
AMKL have a three year survival as high as 91%, [10] a characteristic that appears to be 
related to a greater susceptibility of leukemic clones to conventional chemotherapeutic 
agents such as cytarabine. [11]  
 
AMKL caused by the t(1;22)(p13;q13) translocation 
 The second most common cytogenetic abnormality in ch ldren with AMKL is the 
t(1;22)(p13;q13) translocation. [12, 13, 14] This form of AMKL occurs predominantly in 
  3   
very young children, with a median age at diagnosis f only 6 months. [15] The t(1;22) 
translocation brings together the RBM15 gene on chromosome 1 and MKL1 on 
chromosome 22, and results in an in-frame fusion that includes all known functional 
domains of each constituent. [16, 17] The reciprocal MKL1-RBM15 fusion transcript is 
also expressed, but is only 17 or 25 amino acids in length, depending on which RBM15 
isoform in involved, and is not believed to be associated with megakaryoblastic 
leukemogenesis. 
  
Figure 1: A depiction of RBM15, MKL1, and the corresponding fusion products formed 
by the t(1;22)(p13;q13) translocation. 
Image from Ma, Z., Morris, SW., Valentine, V. et al. (2001). Fusion of two novel genes, 
rbm15 and mkl1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 
28, 220-221. [17] 
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RBM15 
 Though this project was specifically focused on the role of MKL1 in 
megakaryocytopoiesis, it is also worthwhile to briefly discuss its partner in the 
t(1;22)(p13;q13) translocation, RBM15. RBM15, also referred to as OTT (for its 
involvement in the one-twenty two translocation) is a member of the spen (split ends) 
family that is conserved from Drosophila. In Drosophila, spen is involved in the 
regulation of EGFR, Ras and Notch-mediated signaling pathways that all can play a role 
in cell-fate decisions. Notch, in particular, has been shown to have a role in the 
development of hematopoietic cells. When the Notch receptor is activated, its 
intracellular domain (NICD) is cleaved, translocates o the nucleus, and interacts with 
CBF1/RBP-Jĸ and an associated corepressor complex. It is thought that NICD activates 
transcription by causing dissociation of inhibitory cofactors such as HDAC-1 (histone 
deacetylase) from CBF1/RBP-Jĸ and, possibly, by helping to recruit other activators. [18] 
Notch1, one of four mammalian Notch receptors, activ tes transcription of HES1, which 
suppresses the activity of the GATA-1 complex. [19] It has been shown that two 
members of the spen family, SHARP (SMRT/HDAC1 Associated Repressor Protein) and 
MINT (which are found in humans and mice, respectivly), inhibit Notch signaling by 
binding to RBP-Jĸ. [20, 21] A study of the crystalline structure of SHARP demonstrated 
that the SPOC domain, which is conserved amongst all pen family genes, mediates this 
interaction. [22] Based on the homology between RBM15 and SHARP, it is surmised that 
RBM15 may also be able to inhibit the Notch signalig pathway.  
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 Indeed, experiments conducted in the Krause lab have demonstrated a role for 
RBM15 in myeloid differentiation. A preliminary experiment showed that RBM15-GFP 
binds to RBP-Jĸ and that there is no interaction between RBP-Jĸ and GFP alone. Another 
experiment, using a HES1 driven luciferase assay, showed that 3T3 and HEL (human 
erythroleukemia) cells transfected with either RBM15 or RBM15-MKL1 expression 
cassettes exhibited increased Notch-mediated activation of the HES1 promoter. 
Interestingly, it was found that RBM15-MKL1 increased HES1 activity (and thus, it is 
presumed, GATA-1 suppression) to a greater degree than RBM15 alone. Finally, shRNA-
mediated knockdown of RBM15 caused increased myeloid differentiation of 32DWT18 
cell (a myeloid precursor cell line), while expression of RBM15 inhibited myeloid 
differentiation.[23] Taken together with the finding that GATA-1 is essential for normal 
megakaryocytic differentiation, this suggests that increased activity of the RBM15-
MKL1 product may be involved in megakaryoblastic leuk mogenesis. 
 
MKL1 
 MKL1, also referred to as MAL, BSAC or MRTF-A, is a member of the 
myocardin family of transcription factors, which also includes myocardin and MKL2. 
Members of this family have 35% homology, including several highly conserved 
domains: RPEL repeats involved in actin binding (important for cytoplasmic versus 
nuclear localization, as discussed below); a basic "B box" and a glutamine-rich domain 
which bind Serum Response Factor (SRF); SAP (SAF-A, acinus, PIAS), which is thought 
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to bind matrix attachment regions (MARs) of active chromatin, though deletion has no 
effect on transcriptional activity in vitro; [24] aleucine zipper-like domain that may 
facilitate dimerization; and a C-terminal transcriptional activation domain. [25]  
 Investigations into the functions of the myocardin family members have largely 
been focused on the role of myocardin in cardiac and smooth muscle differentiation. 
Myocardin family members can bind Serum Response Factor (SRF) and facilitate the 
expression of genes that have Serum Response Elements (SRE) in their promoters. The 
Serum Response Element in the 5' region of these gen s binds SRF. The SRE typically 
consist of one or more CArG (CC-AT-rich-GG) box, though SRE may also be associated 
with a ternary complex factor (TCF) binding site. It has been shown that p62TCF and 
MKL1 exhibit mutually exclusive binding to SRF, suggesting that these factors may have 
complementary roles in the regulation of the SRF pathw y. 
 MKL1, MKL2 and myocardin are all regulated by a RhoA-actin pathway, which 
controls their cytoplasmic-nuclear translocation. I the presence of G-actin, MKL1 is 
retained within the cytoplasm via its actin-binding RPEL repeat domain. Activation of 
the RhoA pathway induces polymerization of actin into stress fibers, and it is thought that 
the resultant depletion of G-actin allows translocation of MKL1 into the nucleus. [26] 
There is evidence that phosphorylation or sumoylation of these proteins also plays a role 
in the regulation of this movement. [27] Studies in skeletal muscle cells have shown that 
nuclear MKL1 binds to SRF and activates SRE (Serum Response Element) promoters, 
thereby activating transcription of Immediate-Early genes (IEGs) involved in growth (e.g. 
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c-fos) and other genes involved in cellular differentiation and regulation of the actin 
cytoskeleton. [28, 29] In non-hematopoietic cells, transient transfection data show that 
RBM15-MKL1 product increases activation of SRE responsive genes when compared to 
MKL1 alone. [24] 
 A separate study found that BSAC, a murine homolog f MKL1, can inhibit TNF-
α mediated cell death in embryonic fibroblasts. [30] This, too, could represent a 
mechanism by which abnormal activity of MKL1 could contribute to the development of 
leukemia. 
  Surprisingly, a study that examined the effects of MKL -/- knockout mice did not 
identify any significant hematopoietic effects, though several of these mice died in utero 
due to cardiac abnormalities. Additionally, all surviving MKL -/- female mice exhibited 
impaired mammary gland function due to defective myoepithelial cell development, 
resulting in the death of pups born to MKL-/- mothers. [31] 
 Previous findings suggest that MKL1 may have an important role in 
megakaryocytopoiesis in both human and murine cells. Levels of MKL1 mRNA increase 
in E12.5-14.5 murine fetal liver cells that are induced to differentiate along the 
megakaryocytic lineage, with the highest levels found in mature megakaryocytes. [32] In 
the human erythroleukemia (HEL) cell line, which can be stimulated to undergo 
megakaryocytopoiesis with 12-O-tetradecanoylphorbol 13-acetate (TPA), stable 
transduction of a tet-inducible promoter driving expression of MKL1 cDNA and the 
addition of doxycycline leads to a significant increase in the number of mature 
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megakaryocytes (94% vs. 42%) and an increase in the umber of cells with ploidy greater 
than 4N. Gene expression assays using these cells id ntif ed those genes that were 
significantly up- or down-regulated in response to the overexpression of MKL1. These 
included several genes involved in cytoskeletal structure, as well as cdc2, an important 
regulator of megakaryocytic endomitosis. Further experimentation showed that siRNA-
mediated knockdown of SRF completely abrogated the eff cts of MKL1. Thus, it has 
been demonstrated that MKL1 plays an important role in effecting 
megakaryocytopoiesis, and that these effects are mediated by the SRF pathway. 
     
Hematopoietic stem cells 
 Hematopoietic stem cells (HSCs) are pluripotent cells that are capable of 
differentiation into all cell types of the hematopoietic system. In mammalian embryos, 
the earliest stage of hematopoiesis occurs in the yolk sac and is termed primitive 
hematopoiesis. At approximately six weeks of gestation, definitive hematopoiesis arises 
from a region of the dorsal aorta, which is thought to “seed” the liver and spleen, organs 
that are responsible for fetal hematopoiesis, and the bone marrow, which is the site of 
hematopoiesis throughout adulthood. Under disease conditions, the liver and spleen can 
regain some of their fetal hematopoietic functionality. HSCs are quite rare, even in the 
bone marrow, in which they may represent as few as 1 in 20 thousand nucleated cells. 
However, they can be isolated by selecting for and gainst various criteria. For example, 
HSCs are small in size, are negative for markers of lineage commitment (Lin-), and 
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positive for CD34. Thus, a sample of bone marrow can be dramatically enriched for a 
population of hematopoietic precursors. These cells can likewise be isolated from 
umbilical cord blood or from peripheral blood. A common practice for collection of 
CD34+ HSCs from peripheral blood is to administer several doses of G-CSF, which 
stimulates the mobilization of HSCs from within the bone marrow into the bloodstream. 
These cells are consequently called mobilized periph al blood stem cells (PBSCs). 
 HSCs are most commonly isolated for use in stem cell transplants, an important 
therapeutic option for patients with leukemias, lymphomas, and multiple myeloma. There 
has also been investigation into transplant as a potentially curative treatment for patients 
with various non-malignant disorders including metabolic disorders, β-thalassemia, sickle 
cell disease, or serious autoimmune conditions. Studies have also investigated the 
potential role of marrow-derived stem cells in repair of ischemic damage, such as 
following a myocardial infarction, though it is not clear whether HSCs are the cells that 
are responsible for promoting repair.  
 HSCs also represent a highly valuable investigation l tool for the study of 
hematopoiesis. In this project, HSCs are an ideal model to study the effects of the gene of 
interest, MKL1, on the process of megakaryocytopoiesis. 
 
Megakaryocytopoiesis 
 Megakaryocytopoiesis is the process by which pluriotent hematopoietic cells 
differentiate and mature into megakaryocytes, culminating in the release of platelets. This 
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is a complex and tightly regulated process, essential for the maintenance of the 
thrombopoietic system. In general, megakaryocytopoiesis occurs in the bone marrow, 
However, as a few CD34+ hematopoietic precursors circulate in the peripheral blood, it is 
possible for some of these cells to engraft in organs such as the spleen and undergo 
extramedullary megakaryocytopoiesis. This is thought to represent a minor percentage of 
megakaryocytopoiesis. 
 One of the earliest markers of megakaryocytic progenitors is the platelet 
glycoprotein complex IIa/IIIb (GP IIa/IIIb). These markers are also known as CD41a 
(GPIIb) and CD61 (GPIIIa). CD41 is present on approximately 2% of bone marrow 
CD34+ cells. The earliest identified megakaryocytic progenitor is called the 
megakaryocyte high-proliferative-potential colony forming cell (Mk-HPP-CFC), which 
has a remarkably high proliferative capacity, forming large colonies that are visible 
without a microscope. [33] The Mk-HPP-CFC successively give rise to megakaryocyte 
burst forming units (BFU-MK) and megakaryocyte colony forming units (CFU-MK), 
which have progressively decreasing capacity for prlife ation. 
 The process of megakaryocytopoiesis continues with the development of 
promegakaryoblasts. These cells can not yet be identified by morphologic criteria, but 
begin expressing additional megakaryocyte-associated markers, such as platelet 
peroxidase, von Willebrand factor and platelet glycoprotein Ib (also referred to as 
CD42b). 
 As the cells continue to mature, there is a progressiv  increase in the volume of 
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cytoplasm and increased numbers of platelet specific granules. Mature megakaryocytes 
are capable of undergoing DNA replication without cell division, a process termed 
endomitosis. Thus, mature megakaryocytes can acquire DNA content with a ploidy of 
64N or greater. These cells are also remarkable for a very high degree of expansion of the 
plasma membrane, which, due to complex cytoskeletal r arrangements, forms a network 
called the demarcation membrane system. The cell fina ly forms long appendages called 
proplatelets, and the cell undergoes apoptosis, releasing as many as 5,000 platelets per 
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Statement of purpose 
 
  Acute Megakaryoblastic Leukemia with the t(1;22)(p13;q13) chromosomal 
translocation is a form of myeloid leukemia that affects infants and very young children. 
It is poorly understood how the t(1;22) translocation and its resultant fusion of RBM15-
MKL1 promotes megakaryoblastic leukemogenesis. It is likely that the RBM15-MKL1 
fusion product has a different activity than wildtype MKL1, possibly acting on pathways 
affecting megakaryoblastic differentiation and proliferation. The purpose of this project 
was to investigate the effects of MKL1 on normal megakaryocytopoiesis. Determining 
whether MKL1 plays a role in megakaryocytopoiesis is a crucial first step toward 
understanding the fusion protein, which could lead to the design of novel, targeted 
therapies for infants with AMKL. 
 Human CD34+ hematopoietic progenitor cells were used as a model t  study the 
effects of MKL1 on megakaryocytopoiesis. These cells were transduced with viral 
vectors expressing MKL1 or dominant negative MKL1 and were cultured in conditions 
that favor megakaryocytopoiesis. Cells were assessed for morphologic evidence of 
differentiation, expression of megakaryocyte-associated antigens and the presence of 
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Figure 2: This schematic illustrates the overall experimental pl n, in which CD34-
selected human mobilized peripheral blood hematopoietic stem cells are transduced with 
lentiviral vectors expressing MKL1 or dominant negative MKL1, and then cultured in 
conditions that favor megakaryocytopoiesis. The cells are then assessed for morphologic 
and phenotypic evidence of megakaryocytic differentiation and maturation. 
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Materials and methods 
 
Construction of retroviral and lentiviral plasmids (James Troy, Matthew Renda and 
Lin Wang) 
 Human and murine pcDNA3-MKL1 plasmids were generously provided by 
Stephan W. Morris, St. Jude's Children's Research Hospital. 
 A human dominant negative MKL1 plasmid, pCMVx3-FLAG7.1-C630, was a 
generous gift from Dr. Ron Prywes, Columbia University. This plasmid includes the first 
630 amino acids of the hMKL1 coding sequence, and acts s a dominant negative MKL1 
by suppressing MKL1 activity on SRE-containing reporters. [24] Dr. Prywes also 
donated pm18, a Luciferase reporter with a modified c-fos promoter containing a CArG 
box (a SRF binding site) but without a binding site for ternary complex factor (TCF). 
pm18 is one of the reporters that has been used to test dominant negative MKL1 function, 
and was similarly used in this work. 
 The lentiviral plasmid, pCCL-C-MND, was generously provided by Dr. Carolyn 
Lutzco, Children's Hospital of Los Angeles. [34] pCCL-C-MND includes a 
phosphoglycerate kinase (PGK) promoter driving exprssion of GFP, and a second 
promoter, MND, which can be used to express an inserted coding sequence. This MND-
driven site was used to create MKL1 and dominant negative MKL1 expressing lentiviral 
vectors. 
 A retroviral MKL1 vector, MigR1-human C630, was made by digesting 
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pCMVx3-FLAG7.1-C630 with Ssp I and Hinc III, digesting MigR1 (MSCV-IRES-GFP, 
a vector derived from murine stem cell virus) with Hpa I, and ligating the appropriate 
fragments with T4 DNA ligase. Subsequent sequencing identified a known 150 bp 
deletion within the C630 coding region, present on he parent vector. 
 pCCL-human C630 was prepared by digesting both pCCL- -MND and MigR1-
human C630 with EcoRI and ligating the appropriate fragments. 
  A murine dominant negative MKL1 variant was designed by performing two 
successive mutagenesis reactions on MigR1-murine MKL1, which includes an in-frame 
C-terminal His tag. First, a Bsi WI site was created at approximately position 630. A 
second Bsi WI site was added at the end of the MKL1 coding sequence, but prior to the 
His tag coding sequence. This plasmid was digested with Bsi WI to excise the region 
between the two Bsi Wi restriction sites and religated with T4 DNA ligase. This brought 
about a truncated MKL1 coding sequence but kept the His tag sequence in frame. 
  MigR1-human MKL1 was initially difficult to clone directly, so it was made by a 
complicated strategy that started with MigR1-FLAG-C630 plasmid, a dominant negative 
construct that includes a truncated MKL1 sequence. MigR1-FLAG-C630 and pcDNA-
FLAG-human MKL1 were digested with Sfi I and Bam HIin order to append the latter 
portion of the MKL1 coding sequence onto the dominant negative construct. However, 
this has a 150 bp deletion within the MKL1 sequence, as noted above. Thus, a multiple 
cloning site (MCS) was inserted upstream of MKL1, and Mlu I (within the MCS) and Sfi 
I were used to excise the first portion of the MKL1 coding sequence, which included the 
  16   
deletion, and this was replaced using a different fragment from pcDNA-FLAG-human 
MKL1. 
  To prepare the MKL1-expressing lentivirus, pcDNA-FLAG-human MKL1 was 
digested with Bam HI, and Klenow fragments were used to create blunt ends. These blunt 
ends were ligated with an Eco RI linker. The resulting plasmid was digested with Eco RI 
and ligated to an Eco RI digested fragment from the pCCL-C-MND lentiviral vector. 
 A murine MKL1 lentivirus was prepared in a similar manner as the human 
version described above. The pCCL-C-MND lentiviral vector was digested with Eco RI 
and Klenow fragments were used to create blunt ends. The lentiviral vector backbone was 
ligated to a Pme I digested insert from the pcDNA-murine MKL1 plasmid. 
   
Luciferase assays 
 Several dominant negative MKL1 plasmids were obtained or produced in order to 
assess the effects associated with blocking MKL1 activity. The pcDNA-hMKL1 C630 
plasmid was generously provided by Dr. Ron Prywes, Columbia University. C630 
includes the first 630 bases of the human MKL1 coding sequence. As described above, 
the MKL1 C630 coding sequence was cloned into MigR1 to create a retroviral vector. A 
murine dominant negative vector was also designed by truncating the MigR1-mMKL1 
coding sequence at the equivalent position in the murine MKL1 coding sequence. 
 HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) plus 
10% fetal bovine serum (FBS), 2 mM L-glutamine (Gibco) and penicillin/streptomycin 
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(Gibco). When the cells reached greater than 90% confluence, the media was changed to 
antibiotic-free DMEM plus 10% FBS and 2mM L-glutamine. Cells were transfected with 
the pm18 Luciferase reporter, the PRL-TK Renilla contr l, and varying combinations of 
the pcDNA-hMKL1 and dominant negative MKL1 constructs described above. The 
pcDNA backbone was added to normalize the total amount f DNA in each sample. The 
transfection was performed in the presence of Lipofectamine 2000 and Opti-MEM for a 
total incubation of 5 hours. After transfection, the cells were allowed to recover overnight 
in DMEM plus FBS and L-glutamine. This was followed by a period of serum starvation, 
in which the cells were incubated in DMEM plus 0.2% FBS and L-glutamine for 24 
hours, to block early serum-stimulation of the RhoA actin pathway. Finally, cells were 
placed in DMEM plus 20% FBS for three hours. 
 To prepare the samples for the Luciferase assay, cells were lysed with the 
Luciferase assay lysis buffer and briefly frozen at -80º C. The assay was performed on an 
automated luminometer, which adds 100 mcL successivly of each of the Firefly 
Luciferase and Renilla substrates (Biotium) and measures the light output at the 
appropriate intervals. These experiments were performed in triplicate and p values were 
calculated by performing unpaired t tests on the relativ  Luciferase/Renilla values. 
 
Production and purification of retroviral and lentiviral vectors 
 Retroviruses and lentiviruses were prepared as vectors for the delivery of MKL1 
and dominant negative MKL1 expressing cDNA. To make Mig-MKL1, Mig-DN-MKL1, 
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and the Mig R1 control, these plasmids were cotransfected with the PCL Ampho 
packaging vector into 293FT cells in Opti-MEM media supplemented with 
Lipofectamine 2000. The cells were incubated for 5 hours, after which the media was 
changed, and the cells were subsequently incubated in DMEM plus 10% FBS, L-
glutamine and penicillin/streptomycin. Starting on the day after transfection, the virus-
containing supernatant was collected for 3 days. The supernatant was filtered through a 
0.45 um syringe filter (to remove cellular debris) and concentrated in a centrifugal filter 
unit (Amicon Ultra-15) at 4000 rpm in a Sorvall RT7 centrifuge for approximately 20 
minutes at 4º C. This concentrated viral supernatant w s frozen at -80º C. A sample of the 
virus was titrated by a titered transduction of HeLa cells, assessed for GFP expression by 
FACS. 
 Lentiviral concentrates were formed in a similar manner to make pCCL-MKL1, 
pCCL-DN-MKL1, and the pCCL vector control. These lentiviral plasmids were 
cotransfected into 293FT cells with the packaging, rev and vsv-g plasmids in Opti-MEM 
and Lipofectamine 2000, as described above. Supernatant was likewise collected each 
day for the following three days. However, the lentiviral supernatant was filtered through 
a large-volume 0.45 um bottle-top flask (Sigma-Aldrich) and concentrated by 
ultracentrifugation in a Beckman SW41 rotor at 25,000 rpm for 2 hours at 4º C. After 
forming a viral pellet, the supernatant was removed, the virus was resuspended and 
frozen as described above. The lentiviral preparations were also titered in HeLa cells. 
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CD34+ HSC collection (Wendy Haskell) 
 Healthy human donors were injected with G-CSF to mbilize CD34+ HSCs. 
Peripheral blood mononuclear cells were collected by apheresis for the primary purpose 
of HSC transplantation. CD34+ cells were isolated by immunomagnetic selection, using 
the Baxter Isolex Cell Separation Device (Miltenyi Biotec). These cells were 
cryopreserved in 10% DMSO. The use of human subjects was approved by the Yale 
Institutional Review Board (IRB). Surplus cells from these collections were used in the 
following experiments. 
 
Thawing CD34+ HSCs (adapted from Stem Cell Technologies protocol) 
 Frozen vials of CD34+ HSCs were thawed quickly in a 37º C water bath. Cells 
were transferred to a 50 mL conical tube (Falcon). 15 mL of Iscove's modified 
Dulbecco's medium (IMDM) plus 2% FBS and penicillin/streptomycin (Gibco) were 
added dropwise. The tube was subsequently filled to 50 mL with the same media and 
gently mixed. The cells were pelleted by centrifugation at 1000 rpm for 10 minutes. 
Supernatant was removed and the cells were resuspended at a concentration of 100,000 
cells/mL in serum free expansion media (SFEM, Stem Cell Technologies) plus 
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Determination of optimal cytokines to induce human mobilized peripheral blood 
CD34+ cells to undergo megakaryocytopoiesis 
 CD34+ cells, as described above, were cultured in various cytokine combinations 
in order to determine the ideal conditions for megakaryocytopoiesis. The following 
cytokine combinations were tested: 100 ng/mL thrombpoietin alone; 100 ng/mL 
thrombopoietin plus 50 ng/mL stem cell factor; and 100 ng/mL thrombopoietin, 50 
ng/mL stem cell factor (SCF) and 0.01 ng/mL IL-3 (all cytokines purchased from 
Peprotech). 
 Proliferation of these cells was assessed every 2-3 days by staining non-viable 
cells with Trypan Blue and counting the remaining cells on a hematocytometer. 
Cytospins were performed to assess the degree of megakaryocytic differentiation in 
response to culture with various cytokines. CD34+ cells were adjusted to a concentration 
of 10,000-20,000 cells / 100-200 mcL in SFEM media. These samples were placed onto 
glass microscopic slide by centrifugation in the Cytospin apparatus at 500 rpm for 7 
minutes. Slides were air dried, then stained with Wright-Giemsa. The cytospins were 
examined using an Olympus BX51 microscope, and images were collected with a Cooke 
Sensicam QE camera. Uniform segments of each slide wer counted for the total number 
of cells and the total number of megakaryocytes under each culture condition.  
 FACS experiments were also performed to assess the expression of 
megakaryocyte-associated markers. Samples composed of 100,000-200,000 cells were 
washed with FACS buffer plus 10% FBS, and distributed into a V-well plate. Samples 
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were incubated with anti-CD32 to block non-specific b nding, washed again, and then 
incubated with various combinations of differentiation-specific antibodies, including anti-
CD41a, anti-CD42b, anti-CD61, anti-CD13 and anti-CD33. The corresponding 
immunoglobulin isotypes were used as controls. Cells were analyzed by FACS using a 
FACSCalibur and the FlowJo flow cytometry software. 
 
Comparison of retroviral and lentiviral transduction efficiency in human CD34+ cells 
 Human mobilized peripheral blood CD34+ cells were thawed as previously 
described and cultured in SFEM (StemCell Technologies) plus 100 ng/mL TPO 
(Peprotech), 50 ng/mL SCF (Peprotech), 2 mM L-glutamine (Gibco) and 
penicillin/streptomycin (Gibco). On days 1 and 2, cells were transduced with the GFP-
expressing MigR1 virus, GFP-expressing pCCL lentivirus, or underwent a mock 
transduction, by spinfection in a Sorvall RT centrifuge at 1000 rpm for 2 hours at 32º C 
in the presence of 8 ng/mL polybrene. After spinfection, the media was changed and the 
cells were allowed to recover overnight. Cells were subsequently analyzed by FACS for 
the expression of GFP, to determine whether the retroviral or lentiviral vectors were 
optimal for transduction of these cells. 
 
Comparison of polybrene and Lipofectamine 2000 as transduction enhancing agents 
 There is evidence in the literature that Lipofectamine 2000 may serve as a better 
transduction-enhancing agent than polybrene for human CD34+ cells. [35] Thus, we 
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performed a direct comparison of polybrene and Lipofectamine 2000, using the pCCL-
dominant negative MKL1 virus. Two-day differentiated human mobilized peripheral 
blood CD34+ cells were distributed evenly (approximately 230,00  cells/well) into four 
separate wells of a 12-well plate. Three wells received aliquots of pCCL-DN-MKL1 
virus. The final well received an equivalent volume of DMEM plus 10% FBS, to serve as 
a mock transduction control. All wells were adjusted to include 100 ng/mL TPO, 50 
ng/mL SCF, 2 mM L-glutamine and penicillin/streptomycin. Separate wells received 
either polybrene (at a final concentration of 8 ng/mL) or Lipofectamine 2000 (either 1 
mcg or 10 mcg in a total volume of 1 mL). Samples were centrifuged at 2000 rpm for 2 
hours at 37º C. After spinfection, the media was replaced with fresh SFEM plus TPO, 
SCF, L-glutamine, and penicillin/streptomycin at the concentrations listed above. After 2 
days, cells were assessed by FACS for the expression of GFP, and data was analyzed 
with the FlowJo flow cytometry software. 
 
FACS Analysis of MKL1 and dominant negative MKL1 transduced cells (James Troy 
and Matthew Renda) 
 Human mobilized peripheral blood CD34+ cells were thawed as previously 
described and cultured in SFEM (StemCell Technologies) plus 100 ng/mL TPO 
(Peprotech), 50 ng/mL SCF (Peprotech), 2 mM L-glutamine (Gibco) and 
penicillin/streptomycin (Gibco). On day 2, the cells were pelleted, resuspended in a total 
volume of 1.5 mL, and distributed into 3 wells of a 12-well plate. Each well received 
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either pCCL, pCCL-MKL1, or pCCL-DN-MKL1 viral supernatant, or an equivalent 
volume of DMEM. Transductions were performed at a multiplicity of infection (MOI) of 
approximately 50-100, except for pCCL-DN-MKL1, whic had MOI of only 
approximately 5 due to lower viral yields. Cytokines, L-glutamine and 
penicillin/streptomycin were present in the same concentrations as listed above. 
Polybrene was added at a concentration of 8 ng/mL, and plates were “spinfected” in a 
tabletop centrifuge at 1000 RPM, 32° C, for 2 hours. An additional 2 mL of complete 
medium was added and the cells were incubated for at least 10 hours to recover. A 
second spinfection was then performed as described a ove, after which the cells were 
placed in fresh medium at a concentration of approximately 100,000 cells/mL.  
 On day 9, the cells were prepared for FACS analysis, to determine the expression 
of megakaryocyte-associated markers and the expression of other lineage defining 
markers. Cells were incubated with anti-CD32 to block non-specific binding, and then 
incubated with anti-CD41a, anti-CD42b, anti-CD61, anti-CD13 and anti-CD33. Cells 
were counted on a BD FACSCalibur and analysis was performed using the FlowJo flow 
cytometry software. 
 Cells from the same donor were used for all repeats of this experiment, to avoid 
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Assessment of the effect of Retronectin on the efficiency of lentiviral transduction into 
CD34+ cells 
 In one experiment, a direct comparison was made to determine the potential 
benefit of using Retronectin-coated plates for lentiviral transduction into CD34+ cells. A 
50 mcg/mL solution of Retronectin was prepared and d ed to one well of a non-tissue 
culture treated plate. After incubation for 2 hours at 25º C, the Retronectin solution was 
replaced with a 2% BSA for another 30 minutes. The plate was then washed with PBS 
and stored at 4º C until use. The transduction protocol was otherwise performed as 
described above. 
 
Megakaryocyte progenitor assays (James Troy and Matthew Renda) 
 CD34+ cells were thawed, cultured and “spinfected” as decribed above with 
pCCL and pCCL-MKL1, except that on day 4, cells were underwent FACS sorting to 
isolate GFP+ expressing cells. 
 Cells were pelleted and resuspended in 5 mL PBS plus 0.5% FBS, filtered through 
a coarse filter to remove cell clumps, pelleted in a FACS tube, and resuspended in 
approximately 500 mcL PBS plus 0.5% FBS. The samples w re subsequently kept on ice, 
and sorted for GFP+ cells by the flow cytometry technician using a Dako MoFlo cell 
sorter. The cells were resuspended in the complete m dium described above. 
  On day 5, sorted cells were used to perform a MegaCult-C assay. Cell 
concentrations were adjusted to give either 5,000 or 20,000 cells per chamber. The 
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medium was IMDM plus 50 ng/mL rhTPO, 10 ng/mL rhIL-6 and 10 ng/mL rhIL-3. 
Slides were incubated at 37° C for 12 days.
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Results 
  
Assessment of dominant negative MKL1 suppression of SRE activation 
  Three different dominant negative MKL1 constructs, pcDNA-hMKL1 C630, 
MigR1-hMKL1 C630, and MigR1-mMKL1 C630 were assessed for ability to suppress 
activity of MKL1. pm18, a modified c-fos promoter was used as the reporter in 
Luciferase assays because the c-fos promoter contains a Serum Response Factor binding 
site. As shown in Figure 3, transient transfections f three dominant negative constructs 
had the ability to significantly suppress the activity of both exogenous and endogenous 
MKL1. In particular, the pcDNA-hMKL1 C630 construct reduced the activity of 
exogenously added MKL1 by 96% (p < 0.0001). The human and murine MigR1 
dominant negative constructs reduced activity by 20% (p < 0.05) and 36% (p < 0.005), 
respectively. In the absence of exogenous MKL1, I also ssessed the effect of dominant 
negative MKL1 on endogenous MKL1 activity. pcDNA-hMKL1 C630 reduced the 
activity of endogenous MKL1 by 87% (p < 0.005), compared to 76% (p < 0.005) and 
86% (p < 0.005) seen with the human and murine MigR1 samples. 
 A similar experiment was conducted to test the effcts of these three dominant 
negative constructs on the activity of murine MKL1. As shown in Figure 4, pcDNA 
mMKL C630 was highly effective at suppressing the activity of exogenous mMKL1 on 
the pm18 reporter. However, in this setting, the MigR1 dominant negative constructs 
(including the murine MKL1 C630) did not significantly block the activity of mMKL1. 
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Figure 3: Comparison of the ability of three human dominant negative constructs to 
suppress the activity of exogenous (columns 1-4) and endogenous (columns 5-8) human 
MKL1 on a Serum Response Element reporter. The Firefly luciferase readings were 
normalized against a Renilla control. 
 
Figure 4: Luciferase assays were also performed to compare the ability of the three 
dominant negative MKL1 constructs to suppress the activity of exogenous murine 
MKL1. The Firefly luciferase readings were normalized against a Renilla control. 
pcDNA dominant negative hMKL suppresses the 
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HSC culture and differentiation 
  Human CD34+ hematopoietic progenitor cells were cultured in media containing 
various combinations of thrombopoietin (TPO), stem cell factor (SCF) and interleukin-3 
(IL-3) in order to determine the ideal conditions i which to induce these cells to undergo 
megakaryocytopoiesis. The use of TPO alone yielded the highest proportion of 
megakaryocytes after 9 days, as measured by the expr ssion of megakaryocyte-associated 
markers (such as CD41/61, found on immature and mature megakaryocytes) and by 
morphology, which assesses only mature cells. For example, in one experiment, 50% of 
cells cultured in thrombopoietin alone were CD41+, compared to only 28% of cells 
cultured with TPO plus SCF, or TPO, SCF and IL-3. However, the cells cultured in TPO 
alone had the lowest degree of expansion. The addition of SCF yielded a lower 
percentage of megakaryocytes but increased numbers of cells, due to either increased 
proliferation or survival. Cells cultured with TPO plus both SCF and IL-3 had the 
greatest degree of expansion and the lowest proporti n of megakaryocytic differentiation. 
FACS results, cell counts, and representative images from day 9 cytospins are shown in 
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Figure 5: Proliferation and megakaryocytic differentiation of human CD34+ cells in 
various cytokines. A. Cells were counted at regular intervals to assess the degree of 
proliferation. B. Flow cytometry was performed to determine the expression of 
megakaryocyte-associated markers CD41a, CD61 and CD42. CD13 was used to assess 
myeloid cell differentiation. C. Cytospins were preared and examined microscopically 
to assess the degree of megakaryocytic maturation. Tpo = thrombopoietin, SCF = stem 
cell factor, IL3 = interleukin-3. 
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Lentivirus is more effective than retrovirus for the transduction of human CD34+ HSC 
 Human CD34+ peripheral blood stem cells were transduced with GFP-expressing 
lentivirus (pCCL) or retrovirus (MigR1) to determine which vector is more effective in 
these cells. Cells were assessed by FACS to determin  the percentage of GFP+ cells, 
using cells which underwent a mock transduction as the control. Transduction with pCCL 
was associated with GFP expression in 27% of cells, while MigR1 only transduced 6% of 
cells. 
Figure 6: Comparison of the transduction efficiencies of MigR1 and pCCL viral vectors 
into human CD34+ hematopoietic stem cells. Cells were analyzed by flow cytometry for 
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Retronectin does not increase the lentiviral transduction efficiency of CD34+ cells 
 Retronectin is thought to improve viral transduction efficiency by binding both 
viruses and cells, and bringing these into close proximity. [36] A direct comparison was 
performed to determine if Retronectin is beneficial for the transduction of VSV-G 
pseudotyped lentivirus into peripheral blood CD34+ cells. CD34+ cells were transduced 
with pCCL-MKL1 using identical protocols, except some cells were placed in a 
Retronectin-coated well. As shown in Figure 7, the transduction efficiency in the 
presence of a Retronectin-coated well was approximately 12%, compared to greater than 
15% without the addition of Retronectin. 
Figure 7: Human CD34+ cells were transduced with lentivirus, with and without the 
presence of Retronectin. Flow cytometry was performed to assess the expression of GFP, 
and to determine whether Retronectin was beneficial in enhancing the transduction 
efficiency in these experiments. Retronectin was not found to be beneficial for lentiviral 
transduction of human PBSCs. 
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Polybrene enhances lentiviral transduction of human CD34+ cells 
 Human CD34+ cells were transduced with the pCCL-dominant negative MKL1 
virus using either polybrene or Lipofectamine 2000 as a transduction-enhancing agent. 
Additionally, Lipofectamine 2000 was tested at two different concentrations. In Figure 8, 
it is shown that the highest transduction efficiency, 12%, was obtained with the use of 
polybrene. The Lipofectamine 2000 samples had 9% and 7% efficiencies at the low and 
high doses, respectively. 
Figure 8: Two polycations, polybrene and Lipofectamine 2000, were compared as 
“transduction-enhancing agents” for the lentiviral transduction of human CD34+ cells. 
Polybrene was associated with a higher transduction efficiency than Lipofectamine 2000. 
Note that higher concentrations of Lipofectamine 2000 were also inversely correlated 
with lower rates of transduction. 
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FACS Assays 
 Human peripheral blood CD34+ cells were transduced with either pCCL, pCCL-
MKL1, pCCL-DN-MKL1 or underwent a mock transduction. On day 9, FACS was 
performed to assess the expression of megakaryocyte-associated antigens such as CD41a, 
CD42b and CD61. As shown in Figure 9, transduction with the MKL1-expressing virus 
was associated with an increase in expression of each of these megakaryocytic markers 
when compared to the pCCL control. For example, the pCCL-MKL1 transduced cells 
were, when averaged across four experiments, 52±10% CD41a+, 46±17% CD42b+ and 
56±15% CD61+. In contrast, the pCCL cells were 28±15% CD41a+, 26±13% CD61+ and 
14±5% CD42b+. P values for each of these markers were < 0.05, using paired t tests for 
the four pairs of parallel samples. In one experiment, dual staining with both CD41a and 
CD61 also demonstrated that these cells were almost entirely dually positive, consistent 
with the heterodimeric fibrinogen receptor that these factors are known to form. 
 Surprisingly, cells transduced with pCCL-DN-MKL1 had a similar, if not greater, 
increase in megakaryocyte antigen expression, though due to poor transduction 
efficiencies, this experiment was only performed once. In this single experiment, the 
GFP+ fraction was also 65% CD41a+, 68% CD42b+, and 92% CD61+ (data not shown), 
greater than pCCL or pCCL-MKL1 transduced cells that were incubated and prepared in 
parallel. As this experiment was only performed once, it will require further 
investigation. 




Figure 9: Several experiments were performed to determine the effects of MKL1 and 
dominant negative MKL1 on megakaryocytopoiesis in human CD34+ hematopoietic stem 
cells. Cells transduced with either pCCL-MKL1 lentivirus were compared to both a 
“mock” control and to cells transduced with the lentiviral vector alone. The pCCL-MKL1 
transduced cells consistently had greater expression of megakaryocyte-associated 
markers than the pCCL control.  
 
Megakaryocyte progenitor assays 
 We assessed the effect of MKL1 on differentiation of megakaryocytic progenitors 
from human CD34+ peripheral blood stem cells. CD34+ cells were transduced with 
lentiviral vectors expressing either GFP or both GFP and MKL1. In four different 
experiments, transduction with pCCL-MKL1 was associated with an increase in the 
number of megakaryocytic colony forming units (CFU-Mk), compared to cells 
transduced with pCCL alone, though this finding didnot reach statistical significance. 
pCCL-MKL1 was also associated with a trend decrease in the number of non-
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megakaryocytic CFU. Surprisingly, both pCCL and pCCL-MKL1 were associated with 
greater numbers of CFU-Mk in comparison to cells which underwent a mock 
transduction. As an additional control in some experim nts, the GFP- fraction from the 
sorts were also used in some of the CFU-Mk assays. Although transduction with pCCL-
MKL1 was associated with significant increase in CFU-Mk versus the GFP- cells, the 
same effect was seen with the cells transduced with pCCL only. Some unsorted (“pre-
sort”) cells were also tested, to determine the effcts of sorting on the survival and/or 
differentiation of megakaryocytic progenitors. In general, the process of sorting was 
associated with a decrease in the total numbers of CFU-Mk. 
 
Figure 10: Human CD34+ hematopoietic stem cells were transduced with pCCL-MKL1 
or pCCL, and sorted for GFP-expressing cells as indicated. These cells were placed into 
megakaryocyte progenitor assays and cultured for 12 days. Slides were then stained and 
read for the presence of megakaryocyte colony forming units (CFU-Mk) and other 
colonies. In four different experiments, the MKL1-expressing cells yielded greater 
numbers of megakaryocytic progenitors compared to cells transduced with pCCL alone.










MKL1 pCCL mock MKL1 pCCL MKL1 pCCL mock
GFP+ GFP+ GFP- GFP- Pre-sort Pre-sort Pre-sort
























  37   
Discussion 
 
  The goal of this project was to determine the role f MKL1 in the process of 
megakaryocytic differentiation, which is an important step toward understanding the 
mechanism by which RBM15-MKL1 is involved in megakaryocytic leukemogenesis in 
t(1;22)(p13;q13)-associated AMKL. To do so is essential for the development of novel 
targeted therapies for infants with this particularly aggressive form of leukemia. A human 
CD34+ hematopoietic progenitor cell model was developed an  used to demonstrate that 
MKL1 indeed promotes megakaryocytopoiesis. 
 Much of the initial effort in this project was focused on the design and 
construction of various viral vectors. Several of the plasmids used in this work, such as 
human and murine pcDNA3-MKL1, pCMVx3-FLAG7.1-C630 (dominant negative 
MKL1), and the pCCL-C-MND lentiviral vector, were donated from other laboratories. 
These plasmids were used to construct a complete set of vectors including all 
permutations of human and murine, retroviral and lentiviral, and wild-type and dominant 
negative negative MKL1. Luciferase assays demonstrated that the pcDNA3 and MigR1 
DN-MKL1 constructs suppress activity of exogenous and endogenous MKL1 on the 
pm18 reporter. One surprising finding was that the pcDNA3-DN-MKL1 was much more 
effective at suppressing exogenously-added pcDNA3-hMKL1 than either the human or 
murine MigR1 DN-MKL1 constructs. This difference may have to do with different 
levels of cDNA expression between the pcDNA3 or MigR1 plasmids.  
  38   
  Another major component of this work was development of the human CD34+ 
hematopoietic progenitor cell model. There are several published studies which have 
sought to determine the optimal conditions for inducing CD34+ cells to undergo 
megakaryocytopoiesis, adjusting factors such as cytokines and temperature. For example, 
some researchers have attempted to use combinatorial techniques to evaluate the roles of 
numerous cytokines, such as thrombopoietin, stem cell factor, Flt-3 ligand, and many 
others. [37] However, these studies have not always agreed on the ideal combination of 
cytokines. Furthermore, different investigators have used different sources of 
hematopoietic stem cells, which may have different responses to equivalent cytokines. 
For example, there are several very significant differences between HSCs derived from 
bone marrow versus peripheral blood or umbilical cord blood, and these differences may 
impact the cells' ability to differentiate along the megakaryocytic lineage. Though some 
reports indicate the ability to create a highly pure population of megakaryocytes using 
thrombopoietin alone, [38] this sort of result has not been published using mobilized 
peripheral blood HSCs. Our findings were that thromb poietin alone yielded the highest 
proportion of megakaryocytes, but even so, the total percentage of cells which resembled 
megakaryocytes by morphology or expressed megakaryocyte-specific markers was 
significantly below some published results using other sources of hematopoietic 
progenitor cells. Moreover, the majority of cells under our culture conditions were 
positive for CD13 and CD33, which are markers of myeloid cells, generally not seen on 
mature megakaryocytes. This is consistent with the finding that CD34+ cells from 
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peripheral blood are much more often CD13+ and CD33+ than CD34+ cells obtained from 
bone marrow. [39] This may be related to the method of mobilization in which donors are 
given several doses of G-CSF. 
 One of the challenges with the CD34+ cells was achieving a satisfactory 
transduction efficiency. A major decision was whether to use a Moloney Murine 
Leukemia Virus (MMLV), such as MigR1, or lentivirus as the vector. MMLV, also 
referred to as oncoretroviruses, were the first form of viruses used for transduction of 
hematopoietic cells. However, these viruses have a major limitation: they require that a 
cell be undergoing cell division for nuclear import and integration of the transgene. This 
can be overcome by stimulating cell division with various cytokines, but this may have 
an unwanted effect on the pluripotency of experimental cells. For this reason, lentiviral 
vectors may be preferred for transgene delivery into HSCs, because they have been 
shown to be able to transduce quiescent HSCs. [40] In a direct comparison, we also found 
that the pCCL lentivirus had a greater transduction efficiency than the MigR1 
oncoretrovirus in the transduction of human mobilized peripheral blood CD34+ cells. 
 There are many other factors that can affect the transduction efficiency of viral 
vectors into hematopoietic cells. For example, the pr sence of cytokines can play an 
important role. A survey done by Zielske et al. looked at the evidence favoring cytokines 
in the lentiviral transduction of HSCs. The majority of studies included in this survey 
found that prestimulation with various combinations of cytokines resulted in higher 
transduction rates than without prestimulation. [41]  
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 Under some conditions, the use of Retronectin (a recombinant fibronectin 
fragment) can improve transduction of hematopoietic cells. The rationale behind this is 
that the Retronectin fragment has domains which are ind pendently capable of binding 
both the viral envelope as well as the membrane of the target cell, thus bringing these two 
elements into close proximity. A benefit has been shown with CD34+ cells and some 
types of lentiviral vectors, [36] but this benefit was not seen in the above experiments 
when using a VSV-G pseudotyped lentivirus. 
 Other factors that have been shown to improve transduction include the use of 
cationic polymers, such as polybrene or Lipofectamine 2000, [35] and the use of a 
“spinfection” or “spinoculation” protocol. [42] Our experiments demonstrated that 
polybrene was associated with superior transduction efficiency compared to 
Lipofectamine 2000. Thus, polybrene was used in all subsequent transductions, though 
transduction efficiencies were still somewhat disappointing. There are few other options 
for increasing the level of transduction for future experiments. One possibility would be 
to attempt to generate a much higher lentiviral titer by dramatically scaling up the virus 
production process. However, this was already being performed at the upper limits of our 
capabilities, with regard to the equipment and materi ls involved. 
 After optimization of the above factors, CD34+ cells were transduced with the 
lentiviral vectors expressing GFP alone, GFP and MKL1, or GFP and dominant negative 
MKL1. The transduction efficiencies for pCCL-MKL1 and pCCL-DN-MKL1 were quite 
low in comparison to the pCCL virus alone. It is possible that the smaller size of the 
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empty viral vector accounts for this difference. In future studies, it may be wise to create 
a control vector of equal size as the pCCL-MKL1 or pCCL-DN-MKL1 plasmids, perhaps 
by inverting the insert coding sequence or by inserting stop codons that prevent 
expression of a full length transcript. Despite these low transduction efficiencies, it is 
possible to analyze such experimental populations by electing for GFP+ cells in a FACS 
analysis or a FACS sort. When examining only the GFP+ cells, transduction with pCCL-
MKL1 was associated with a clear and consistent increase in the expression of 
megakaryocyte-specific markers such as CD41a, CD42b and CD61 in four different 
experiments compared to cells transduced with pCCL alone. However, there was also a 
large percentage of CD13+ and CD33+ cells in this experiment, suggesting some degree 
of granulocytic differentiation. Moreover, the percntage of cells positive for 
megakaryocytic markers plus the percentage of cells positive for granulocytic markers 
exceeded one hundred percent, which means there was some overlap between these two 
populations. 
 Perhaps the most surprising result found during this experiment was that cells 
transduced with dominant negative MKL1 lentivirus had a similar trend as those 
transduced with normal MKL1. That is, both MKL1 and dominant negative MKL1 were 
associated with an increase in cells positive for CD41a, CD42b and CD61. However, the 
pCCL-DN-MKL1 experiment was performed only once. Given that previous experiments 
using HEL cells have shown that MKL1 induces megakaryocytopoiesis via the Serum 
Response Factor pathway, it was expected that the C630 dominant negative MKL1 would 
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inhibit megakaryocytopoiesis by blocking this activity. The mechanism for the increase 
that we observed is completely unclear, though it is possible that dominant negative 
MKL1 can exert some activity via pathways unrelated o SRF, or that it has different 
effects on the SRF pathway at earlier versus later stages of megakaryocytopoiesis. It 
should also be noted that pCCL-DN-MKL1 was not tested for dominant negative activity, 
even though the other DN-MKL1 constructs were shown to suppress MKL1 function. 
However, it is difficult to imagine a mechanism by which a different vector could reverse 
the function of the dominant negative expression product. These interesting DN-MKL1 
results will require further experimentation. 
 The megakaryocyte colony forming unit assays performed in this project provide 
preliminary evidence that transduction with the MKL1 expressing lentivirus increases the 
formation of megakaryocyte progenitors. In four expriments, cells transduced with 
pCCL-MKL1 generated a higher proportion of CFU-Mk than transduction with pCCL 
alone. These experiments were limited by low transduction efficiencies and thus having 
very few positively transduced cells, though, fortunately, these assays require a very low 
number of cells. It is somewhat concerning that transduction with pCCL appeared to 
promote megakaryocyte colony formation versus cells put through a “mock” 
transduction. The mechanism for how the empty virus causes such a trend is unclear and 
is worthy of further investigation. 
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Implications of this work for the understanding and treatment of Acute 
Megakaryoblastic Leukemia 
 There are several forms of leukemia that are known to be associated with various 
chromosomal translocations. In the past, chemotherapeutic regimens consisted entirely of 
drugs which non-specifically impair the cell cycle or are toxic to rapidly dividing cells. 
Though these regimens have proven to be effective in some populations, treatments are 
generally associated with many chemotherapy-related side effects due to toxic effects on 
other cells types in the body. However, the recent decade has been notable for greater 
understanding of the mechanisms by which several chromosomal translocations are 
involved in leukemogenesis, and the development of ovel, targeted treatment options for 
some of these diseases. For example, imatinib mesylat  (Gleevec) was found to be a 
potent inhibitor of the bcr-abl fusion product that is formed by the Philadelphia 
chromosome translocation, t(9;22), in chronic myelog nous leukemia (CML), some cases 
of acute lymphoblastic leukemia (ALL), and rare cases of AML. [43] Gleevec has 
consequently become an important part of therapy for these types of leukemia. 
 However, it is not yet clear how the RBM15-MKL1 fusion product is involved in 
the pathogenesis of t(1;22)(p13;q13)-associated Acute Megakaryoblastic Leukemia, or 
what roles its component genes play in normal megakaryocytopoiesis. In this project, we 
have used a human hematopoietic stem cell model to show that MKL1 is an important 
factor in the process of megakaryocytic differentiation. CD34+ HSCs transduced with 
MKL1 had both increased expression of megakaryocyte-associated markers CD41a, 
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CD42b and CD61, and a trend suggestive of increased numbers of committed 
megakaryocyte progenitors. Thus, it appears probable that one of the mechanisms by 
which RBM15-MKL1 causes enhanced commitment to the megakaryocytic lineage is by 
increased activity of the pathways which MKL1 acts upon in normal 
megakaryocytopoiesis. It is possible that targeted therapies directed at MKL1 and, 
perhaps, other factors in the Serum Response Factor pa hway could one day play an 
important role in the treatment of infants with t(1;22)(p13;q13)-associated AMKL. 
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